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ABSTRACT
Aim: To evaluate the accuracy of our new rapid point-of-care (POC) test for lung maturity.
The method as we describe in an accompanying article was developed with the purpose of
improving the outcome from respiratory distress syndrome (RDS). The test enables the
delivery of surfactant in infants with immature lungs already at birth and ensures that
infants with mature lungs are not treated unnecessarily.
Methods: Fresh gastric aspirate (GAS) was sampled at birth in a cohort of preterm infants
with gestational ages ranging between 24 and 31 completed weeks for lung surfactant
measurement as lecithin–sphingomyelin ratio (L/S). L/S was prospectively compared with
RDS development. The clinical outcome was blinded for the investigators of L/S. The time
for analysis was <15 minutes.
Results: GAS was obtained from 72 infants. Forty-four (61%) developed RDS. The cut-off
for L/S was 3.05; predicting RDS with a sensitivity of 91% and specificity of 79%.
Conclusion: The new improved spectroscopic L/S method of lung maturity on GAS has
high sensitivity. The method is designed for use as a POC test at birth, and a spectroscopic
prototype has been developed for bedside use. Clinical trials with this new lung maturity
test are planned.
INTRODUCTION
Treatment of respiratory distress syndrome (RDS) has
evolved greatly over the past three decades. Major advances
in treatment include antenatal steroids, early nasal contin-
uous positive airway pressure (nCPAP) combined with early
rescue surfactant replacement strategies such as Intubation
Surfactant Extubation (INSURE) (1–3) and Less Invasive
Surfactant Administration (LISA) (3–5), together with use
of lung protective ventilation and overall reduced use of
mechanical ventilation. However, RDS and bronchopul-
monary dysplasia (BPD) are still major causes of mortality
and morbidity in premature infants (3,6). To improve the
outcome, very early treatment with surfactant is necessary
(7). However, only about half of infants with a gestational
age (GA) below 30 weeks need surfactant treatment (8,9)
and prophylactic surfactant treatment increases the com-
bined mortality and incidence of BPD contrary to selective
rescue surfactant treatment (10). Therefore, there is a need
for a rapid test to guide early targeted surfactant treatment
(6,11).
Abbreviations
CI, Confidence interval; FiO2, Fraction of oxygen in inspired gas;
FTIR, Fourier transform infrared spectroscopy; GA, Gestational
age; GAS, Gastric aspirate; IQR, Interquartile range; L/S,
Lecithin–sphingomyelin ratio; LUS, Lung ultrasound score;
nCPAP, Nasal continuous positive airway pressure; POC, Point
of care; RDS, Respiratory distress syndrome.
Key Notes
 Respiratory distress syndrome (RDS) is a major cause of
mortality and morbidity in premature infants, early
targeted surfactant treatment improves outcome.
 We have developed a spectroscopic point-of-care test
to measure lung maturity as lecithin–sphingomyelin
ratio (L/S) in gastric aspirate within the first hour of life.
 L/S was closely correlated to the development of RDS in
72 very preterm infants, and clinical trials with L/S-
guided surfactant treatment are planned.
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Several invasive prenatal tests based on amniotic fluid
such as foam tests, click tests, drop volume methods and
thin-layer chromatography of phospholipids have been
developed over time and have been used to asses lung
maturity before induced deliveries. For an overview see
(12). With the introduction of surfactant treatment for RDS,
additional lung maturity tests based on gastric aspirates
(GAS) were developed; for example, the microbubble
stability test (12–15) and lamellar body counts (16–19)
and our group have previously published a large ran-
domised trial using lamellar body counts to guide surfactant
treatment (19). However, a common problem with all these
methods is dilution with foetal urine. Additionally, the
methods are time-consuming laboratory tests and are too
slow to be used as a point-of-care test (POC) to guide
surfactant treatment.
The sphingomyelin concentration in amniotic fluid and
accordingly in GAS is relatively constant during the
pregnancy, whereas the lecithin concentration increases
with the lung maturation. Thus, when measuring lecithin–
sphingomyelin ratio (L/S) in GAS, the problem with
dilution is avoided (20). The most promising method has
been based on mid-red Fourier Transform Infrared spec-
troscopy (FTIR) (20). Although this method demonstrated a
high sensitivity, it was developed using frozen and thawed
GAS. We have now improved this method for use as a POC
test, optimising it for fresh GAS. The new method combines
dry transmission spectroscopy with concentration of lung
surfactant by centrifugation of the lamellar bodies and
dilution of the proteins. Thereby, we obtain a spectroscopic
amplification of the surfactant signal and omitting interfer-
ence from proteins and cells. The new method is described
in detail in the accompanying article in this number of Acta
Paediatrica (21).
In this article, we describe an observational clinical study
in premature infants in which the clinical course of RDS is
compared with L/S measured at delivery with the new
method.
PATIENTS AND METHODS
The study was a multicentre non-intervention prospective
diagnostic cohort study. The trial was approved by the
regional research ethics committee. Informed oral and
written parental consent was obtained either before or
immediately after birth.
Infants with a GA from 24 to 31 completed weeks were
eligible. GAS should be sampled as quickly as possible
within 45 minutes after birth, as the lamellar body (surfac-
tant) count has been shown to remain stable in GAS up to a
maximum of 45 minutes postpartum (18).
Exclusion criteria were lethal malformations, therapeutic
infusion into the amniotic cavity, and contamination of
GAS by pus or if GAS could not be obtained before
surfactant replacement therapy.
Participation in the study did not interfere with routine
neonatal care. Monitoring and treatment including surfac-
tant replacement therapy in all cases was done in
accordance with the European RDS guidelines (6). Accord-
ingly, rescue treatment with surfactant was done in infants
less than 26 weeks’ gestation when the fraction of inspired
oxygen (FiO2) requirements increased to more than 0.30
and in infants above 26 weeks’ gestation when FiO2
requirements increased to more than 0.40. Immediate
treatment with nCPAP was the primary method of respira-
tory stabilisation at birth, and intubation was only carried
out for resuscitation. To compare the L/S values with the
development of RDS, the included infants were observed
for the first five days of life, as this is the known period
before the surfactant layer is restored after RDS as
described by Avery among others (22). Relevant clinical
data were secured including FiO2, which was registered at
predefined time-points. This also includes factors which
possibly could influence development of RDS and surfac-
tant analyses such as multiple births, asphyxia, antenatal
steroid and pre-existing or gestational diabetes.
RDS was diagnosed when at least two of the four classical
symptoms were present: the need for supplemental oxygen,
tachypnoea, intercostal retractions and grunting, or chest x-
ray consistent with RDS excluding other causes of respira-
tory distress. The severity of RDS was graded in four
categories as in our previous studies (12,20) with minor
modifications. It was graded as Non-RDS if the FiO2 was
< 0.40 in a maximum of six hours after birth, but with short
periods of supplemental oxygen allowed later. Mild RDS
was when FiO2 was 0.22–0.40 for more than six hours after
birth without need for surfactant or mechanical ventilation.
Moderate RDS when there was a need for surfactant or
FiO2 > 0.40, but no mechanical ventilation. Severe RDS was
if there was need for mechanical ventilation within the
study period.
Sampling of GAS and L/S analysis
GAS (0.3–2.5 mL) was collected using a feeding tube
attached to a syringe or a suction catheter connected to a
tracheal suction set. The feeding tube or suction catheters
were placed as routinely done while establishing nCPAP for
respiratory stabilisation or intubation for resuscitation.
GAS was stored at 4–5°C for subsequent L/S analysis
performed as described in our accompanying article in this
number of Acta Paediatrica and without knowledge of the
clinical outcome (21).
Statistical analysis
Because the method is new, sample size calculation was not
possible. Based on our previous trial (20), we estimated that
70 infants with a GA of 24–31 completed weeks (of which
at least 30 would develop RDS) would be sufficient to
evaluate the new method.
Data were expressed as medians (interquartile range). A
cut-off value for L/S that maximised the sum of sensitivity
and specificity to diagnose RDS was determined (23). The
95% confidence intervals (CI) for sensitivity and specificity
were expressed. In addition, the L/S data were stratified
based on GA of 24–25, 26–29 and 30–31 weeks. Pearson’s
chi-square test was used to compare the accuracy of RDS
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prediction from L/S versus gestational age and to examine
the possible influence on the accuracy of L/S from the
mode of delivery, multiple gestation, antenatal steroids,
maternal diabetes and asphyxia (Apgar < 8 at 5 minutes).
Analyses were performed in SPSS version 22, and two-
tailed p values of < 0.05 were considered to indicate
statistical significance.
RESULTS
Infants were enrolled from September 2017 to April 2018
from seven Danish neonatal units. GAS was obtained from
76 infants. Four infants were excluded because GAS had
been frozen, leaving 72 infants in the final cohort.
Clinical characteristics of the included infants are shown
in Table 1. Two infants (3%) died before the end of the five-
day study period. Forty-four (61%) developed RDS, 12
(27%) mild, 14 (32%) moderate and 18 (41%) severe.
L/S from infants with RDS and non-RDS, and the
verification of the cut-off value to predict RDS are shown
in Figure 1. The optimal L/S cut-off value was 3.05. RDS
could be predicted with a sensitivity of 91% (95% CI: 78–
97), specificity of 79% (95% CI: 59–92), positive predictive
value of 87% (95% CI: 74–95) and negative predictive value
of 85% (95% CI: 65–96). Four infants with RDS had L/S
values only slightly higher than the cut-off, from 3.2 to 3.9
(false negative). Six infants without RDS had L/S below the
cut-off value (false positive).
L/S for various degrees of RDS severity and GA are
shown in Table 2. Accuracy of RDS prediction from L/S in
each of the three GA groups 24–25, 26–29 and 30–31 weeks
expressed as sensitivity and specificity was not statistical
different, p > 0.05 for the differences. L/S predicted RDS
more accurately than the GA (Table 3).
In four of seven pairs of twins, the lowest L/S was found
in the second twin and in two pairs in the first twin, while in
one pair L/S was the same in both twins. Prediction of RDS
by L/S did not seem to be influenced by multiple gestation,
antenatal steroid treatment, diabetes or asphyxia, p > 0.05
for the difference. No samples were contaminated with
meconium or pus, and contamination with blood did not
influence RDS prediction (21).
In the study, 32 infants with moderate and severe RDS
were treated with surfactant. Surfactant was administered
before 1 hour of age to six infants; at 1–5 hours of age to
Table 1 Demographic and clinical characteristics of included patients
Characteristics N = 72
GA, median (IQR), week 28.3 (26.9–30.7)
Birthweight, median (IQR), grams 1061 (799–1417)
Caesarean section, n (%) 51 (71)
In labour 36 (71)
Not in labour 15 (29)
Apgar score at 5 minutes, median (IQR) 10 (9–10)
Umbilical pH, median (IQR) 7.29 (7.22–7.33)
Antenatal steroid, n (%) 68 (94)
Surfactant, n (%) 31 (43)
Age in minutes when treated, median (IQR) 240 (90–540)
Ventilated during first 5 days of life, n (%) 18 (25)
Age in minutes, when started, median (IQR) 330 (60–1980)
Dead during the first 5 days of life, n (%) 2 (3)
Male gender, n (%) 41 (57)
Singleton, n (%) 54 (75)
Maternal diabetes, n (%) 7 (10)
IQR = interquartile range.
Figure 1 Lecithin/sphingomyelin ratio (L/S) in gastric aspirates determined by
mid-infrared spectroscopy in 44 infants with RDS and 28 infants with non-RDS.
The best cut-off value is 3.05 moles/mole.
Table 2 Gestational age and L/S-ratio in different degrees of RDS severity
RDS severity
N = 72
n
GA (weeks) LS-ratio (moles/mole)
Median (range) Median(range)
Non-RDS 28 29.4 (25.7–31.7) 4.1 (0–57.8)
Mild RDS 12 30.4 (26.4–31.6) 2.1 (0.6–3.6)
Moderate RDS 14 29.0 (25.4–31.3) 1.0 (0.0–3.0)
Severe RDS 18 26.1 (24.3–31.1) 1.8 (0.0–3.9)
RDS (all degrees) 44 28.0 (24.3–31.6) 1.9 (0.0–3.9)
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nine infants; at 6–9 hours of age to eight infants; at
10–24 hours of age to seven infants; and at 25–48 hours
of age to two infants. None of the six infants with false-
positive L/S values (L/S lower than the cut-off value) were
treated with surfactant.
DISCUSSION
In this observational trial, our new improved L/S method
predicted the development of RDS with a high sensitivity.
The method is based on fresh GAS (21) which is easy and
safe to obtain in any preterm infant within minutes from
birth and the L/S value takes 10–15 minutes to measure. As
our method is fast and based on techniques that can be
automated and do not rely on highly trained laboratory
personnel, it can be developed into a POC test.
As mentioned, FiO2 was used to guide surfactant admin-
istration. Only six infants in our cohort were treated within
the first hour of life and 26 from 1 to 48 hours of life. This
supports the need for a lung maturity test at birth as very
early selective surfactant treatment compared to late selec-
tive surfactant treatment leads to improved clinical out-
come (7). In accordance with this, the European RDS
guidelines also highlights the demand for a fast bedside test
to measure the level of endogenous surfactant to guide
surfactant treatment (6). Screening of lung maturity at birth
is likely to reduce the incidence and severity of both RDS
and BPD (3,19) as it will allow infants with immature lungs
to be treated with surfactant in the first hour of life, while at
the same time protecting infants with mature lungs from
unnecessary surfactant administration and potentially dan-
gerous airway handling. We are currently preparing a paper
in which we will describe the development of BPD in the
cohort from this study, and if possible identify potential
biomarkers for BPD.
De Martino et al. recently evaluated the use of a lung
ultrasound score (LUS) to predict the need for surfactant
therapy in a cohort of preterm infants admitted to a
neonatal unit with extensive experience in lung ultrasound
and found high diagnostic accuracy (24). In a still unpub-
lished study performed in the same unit, LUS-guided
surfactant treatment when compared with treatment as
per the European RDS guidelines (6) resulted in a signif-
icantly but only modestly reduced time to first surfactant
administration from a median of 180 minutes to
165 minutes from birth (25). Our L/S-test can be performed
immediately at delivery, before lung damage from progres-
sion of RDS. In addition, we speculate if LUS may be less
accurate when applied during transition immediately after
delivery. Despite being easy to learn and with high inter-
observer agreement in skilled hands, LUS is subject to inter-
observer variability contrary to our L/S-test and may not be
as reliable in prediction of surfactant deficiency in units less
proficient in lung ultrasound (26).
Surfactant activity in amniotic fluid obtained at birth
measured by a surfactant adsorption test has recently been
shown to correlate with lamellar body counts (18) and LUS
(24) and to be able to predict CPAP failure (27). However,
the method is not a POC test and the analysis takes 60–
90 minutes in a laboratory. Furthermore, amniotic fluid is
not easy to sample in vaginal deliveries and there is a risk of
false-positive values due to dilution of lung surfactant by
foetal urine.
Other clinical factors may influence the development of
RDS. For example, L/S-ratio is often lower in the second
twin compared the first-born twin (22). This tendency was
also seen in this and our previous study (20).
Observational studies including preterm infants in all age
groups from 24 to 32 weeks gestation, like the one we
report here, are planned in Europe and USA and have
already started in China. These studies will generate big
data sets allowing us to calculate the influence from various
factors on RDS prediction.
Similar to our previous study, we found the L/S-test to
have lower specificity than sensitivity (20). All included
infants were stabilised on nCPAP at birth which is a well-
known effective treatment of mild-to-moderate RDS (6).
Consequently, nCPAP may diminish clinical RDS symp-
toms. Six infants with L/S below the cut-off value were
classified as non-RDS and three of those needed intermit-
tent supplemental oxygen for short periods in addition to
nCPAP. This makes it likely that these infants in fact had
subclinical surfactant deficiency. This finding is consistent
with what we have found earlier using the microbubble
stability test and lamellar body counts for early RDS
diagnosis (12,18) and results from other studies measuring
lung maturity at birth (27,28); all studies in which the
included infants were treated with early nCPAP. The cut-off
value for predicting RDS was higher in the present study
(3.05) compared to our previous study (2.2) (20). The main
reason is most likely due to changes in the new biochemical
method (21).
We are continuing our work to develop an effective and
easy-to-use POC method based on our L/S-test (21). We
have developed a prototype of the spectroscope for bedside
use and initiated clinical tests. In the next phase of our
studies, we plan to conduct a randomised trial with the aims
to assess the possible positive effects of the test on relevant
clinical outcomes using the method to guide very early
selective surfactant compared to standard treatment based
on FiO2.
Our method is not limited to measurements of L/S in
GAS, but can be developed further for measurements of L/S
Table 3 Comparison of L/S and gestational age for prediction of RDS
N = 72 of which 44 developed RDS
L/S in gastric aspirate
measured by FTIR GA (week 24–31)
Best cut-off 3.05 moles/mole 27.6
Sensitivity 91% (95% CI: 78–97) 48% (95% CI: 33–63)
Specificity 79% (95% CI: 59–92) 82% (95% CI: 62–93)
Time to diagnosis <1 hour At birth
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and other phospholipids in amniotic fluid, oropharyngeal
fluid, tracheal fluid, for plasma measurements (29) and
measurements in other human fluids.
CONCLUSION
Our new FTIR-based L/S measurement of lung maturity on
GAS at birth has a high sensitivity; the method is very fast
and is without inter-user variability. The method can be
automated; therefore, it can potentially be developed into a
very accurate POC test for use in most neonatal units as a
screening test that would enable prediction of RDS in order
to guide very early targeted surfactant treatment. A POC
test will subsequently be tested in observational and
randomised trials of L/S-guided surfactant treatment vs.
standard neonatal approach.
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